Recent Release | 13 Jul 2020
Trade and transport margins in pharmaceuticals and other R&D-intensive industries
Spending for prescription and over-the-counter pharmaceutical products totaled $413 billion in 2012 according to the Bureau of Economic Analysis’ (BEA) trade and transports margin data. Just over half of this spending (52%) accrued to the pharmaceutical companies that produced the medicines, while the remainder was divided between transport and wholesale margins (21%) and retail margins (26%).
Compared to other research and development (R&D)-intensive manufacturing industries with significant consumer sales, the pharmaceutical and medicines manufacturing industry ranks second in terms of R&D intensity behind communications equipment, and receives the second lowest producers’ share of total spending after other miscellaneous manufacturing. Thus, the pharmaceutical industry is unique among manufacturing industries in that it devotes a large share of its revenue to R&D, despite receiving a considerably smaller share of total spending.
Tags:
You may be interested in
Post
Oxford Economics announces a leadership transition for the next phase of growth
Oxford Economics, the world’s leading economic forecasting and advisory firm, announced today the appointment of Innes McFee as its new Chief Executive Officer, effective 4th December.
Find Out More
Post
Oxford Economics launches enhanced Real Estate Economics Service
Oxford Economics is pleased to unveil its enhanced Real Estate Economics Service, now covering 100 global cities.
Find Out More
Post
Oxford Economics Acquires Majority Stake in Alpine Macro
We're excited to share that Oxford Economics has acquired a majority stake in Alpine Macro, a prominent global investment research firm based in Montreal, Quebec, Canada.
Find Out More
